LH heads into its Q4 earnings report with rising revenue and EPS expectations, driven by Diagnostics momentum, acquisitions and expanding test demand.
Labcorp Holdings Inc. (LH) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
LH's growth bets in specialty testing and acquisitions support its outlook, but macro pressures and currency headwinds remain key risks.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Investors need to pay close attention to LH stock based on the movements in the options market lately.
Labcorp expands in specialty testing and ramps up acquisitions, but macro pressures and currency headwinds complicate its growth outlook.
Labcorp (LH) reported earnings 30 days ago. What's next for the stock?
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Labcorp's Q3 earnings beat forecasts and margins improve, but a trimmed 2025 sales outlook sends shares down.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
While the top- and bottom-line numbers for Labcorp (LH) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Labcorp Holdings (LH) came out with quarterly earnings of $4.18 per share, beating the Zacks Consensus Estimate of $4.13 per share. This compares to earnings of $3.5 per share a year ago.